Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Feb 24;158(5):822–832. doi: 10.1097/j.pain.0000000000000832

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association for the Study of Pain

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

Figure 3. — N46 attenuates inflammation-induced thermal hyperalgesia. (A) One day after CFA injection, N46 (0.01, 0.1, and 0.25 nmol; n = 6, 6, and 11, respectively) was administered intrathecally (arrow). One day later (post-CFA day 2), the rats injected with 0.25 nmol N46 exhibited a significant decrease in heat hyperalgesia compared to the vehicle control (0.1% DMSO in quarter saline, n = 11); P = 0.0007. (B) The mean PWL in the contralateral hind paw. (C) One day after administering CFA, N46 (0.1, and 1 nmol; n = 12 and 7, respectively) was injected into the tail vein (arrow). The next day PWL measurements showed that 0.25 nmol N46 had significantly reduced the heat hyperalgesia compared to the vehicle control (1% DMSO/quarter saline, n = 9); P = 0.0033. (D) The mean withdrawal latency in the contralateral hind paw. Data represent mean ± SEM.